Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery
暂无分享,去创建一个
G. van de Putte | C. V. van Holsbeke | J. Vlasselaer | J. Schobbens | E. D. De Jonge | J. Oben | G. Debrock | Leen Prenen | P. Van Eycken | E. de Jonge | C. Van Holsbeke
[1] G. Scambia,et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. , 2014, American journal of obstetrics and gynecology.
[2] H. Hricak,et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. , 2014, Gynecologic oncology.
[3] Sarah Ferguson,et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. , 2014, Gynecologic oncology.
[4] T. Kasamatsu,et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602. , 2014 .
[5] M. Leeflang,et al. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. , 2014, The Cochrane database of systematic reviews.
[6] G. Scambia,et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. , 2013, Gynecologic oncology.
[7] F. Mowat,et al. An international assessment of ovarian cancer incidence and mortality. , 2013, Gynecologic oncology.
[8] M. Parmar,et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. , 2013 .
[9] I. Vergote,et al. Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? , 2013, Gynecologic oncology.
[10] E. Darai,et al. Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice: A Retrospective French Multicentric Study , 2012, International Journal of Gynecologic Cancer.
[11] B. Ottesen,et al. Neoadjuvant chemotherapy as ovarian cancer treatment: ever more used with major regional differences. , 2012, Danish medical journal.
[12] R. Bristow,et al. Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer , 2012, Annals of surgical oncology.
[13] P. Ghatage,et al. Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery. , 2012, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[14] P. Bossuyt,et al. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study , 2012, BMC Cancer.
[15] D. Levine,et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). , 2012, Gynecologic oncology.
[16] H. Ryu,et al. Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer , 2012, Annals of Surgical Oncology.
[17] J. Schorge,et al. Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer , 2012, Annals of Surgical Oncology.
[18] I. Vergote,et al. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. , 2011, European journal of cancer.
[19] H. Yoshikawa,et al. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions , 2011, Expert review of anticancer therapy.
[20] J. Sehouli,et al. Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.
[21] J. Dungan,et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer , 2011 .
[22] T. Takano,et al. Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. , 2010, The New England journal of medicine.
[23] M. Eijkemans,et al. Prediction of Residual Disease After Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Accuracy of Clinical Judgment , 2009, International Journal of Gynecologic Cancer.
[24] D. Levine,et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. , 2009, Gynecologic oncology.
[25] W. Cliby,et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. , 2009, Journal of the American College of Surgeons.
[26] P. Colombo,et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[27] J. Ajani. The area between the curves gets no respect: is it because of the median madness? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Kimmig,et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). , 2007, Gynecologic oncology.
[29] R. Hariprasad,et al. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): A prospective randomized study—Interim results , 2007 .
[30] J. McAlpine,et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. , 2007, Gynecologic oncology.
[31] B. Karlan,et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Jazaeri,et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. , 2006, American journal of obstetrics and gynecology.
[33] A. Oza,et al. A retrospective analysis of neoadjuvant platinum‐based chemotherapy versus up‐front surgery in advanced ovarian cancer , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[34] J. Kurtinaitis,et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients , 2006, BMC Cancer.
[35] E. Trimble,et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] D. Atallah,et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. , 2003, Journal of the American College of Surgeons.
[37] E. Trimble,et al. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] G. Tulunay,et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma , 2001, International Journal of Gynecologic Cancer.
[39] P. Schwartz,et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.
[40] P. V. van Dam,et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. , 1998, Gynecologic oncology.